Yue S, Motamedi H, Wendt-Pienkowski E, Hutchinson C R
J Bacteriol. 1986 Aug;167(2):581-6. doi: 10.1128/jb.167.2.581-586.1986.
Mutants of Streptomyces glaucescens GLA.0 which are blocked in the production of tetracenomycin C (compound 1), an anthracycline antibiotic having significant antitumor activity, accumulated several new anthracycline metabolites structurally related to compound 1 and to intermediates of its biosynthetic pathway. Through chemical and spectroscopic comparisons with the known anthracycline metabolites of the wild-type strain, we identified the two regioisomers of tetracenomycin B2 (compounds 7a and 7b), 8-demethyltetracenomycin C (compound 12), tetracenomycin D2 (compound 11), tetracenomycin E (compound 13), and the 12-naphthacenone forms of compounds 7a, 7b, and 2 (tetracenomycin D1). A hypothetical biosynthetic pathway to compound 1 is presented that is consistent with the occurrence of compounds 7b, 13, and 5 (tetracenomycin A2) and with the cosynthetic behavior of tetracenomycin C-nonproducing mutants (H. Motamedi, E. Wendt-Pienkowski, and C. R. Hutchinson, J. Bacteriol. 167:575-580, 1986).
在产生具有显著抗肿瘤活性的蒽环类抗生素四环素霉素C(化合物1)过程中受阻的青灰链霉菌GLA.0突变体,积累了几种与化合物1及其生物合成途径中间体在结构上相关的新蒽环类代谢产物。通过与野生型菌株已知的蒽环类代谢产物进行化学和光谱比较,我们鉴定出了四环素霉素B2的两种区域异构体(化合物7a和7b)、8-去甲基四环素霉素C(化合物12)、四环素霉素D2(化合物11)、四环素霉素E(化合物13),以及化合物7a、7b和2(四环素霉素D1)的12-萘并蒽酮形式。本文提出了一条与化合物7b、13和5(四环素霉素A2)的出现以及四环素霉素C非产生突变体的共合成行为相一致的化合物1的假设生物合成途径(H. Motamedi、E. Wendt-Pienkowski和C. R. Hutchinson,《细菌学杂志》167:575 - 580,1986年)。